Advertisement

Applied Health Economics and Health Policy

, Volume 17, Issue 4, pp 433–441 | Cite as

Advanced Data Visualisation in Health Economics and Outcomes Research: Opportunities and Challenges

  • Shelagh M. SzaboEmail author
  • Karissa M. Johnston
  • Andrew J. Lloyd
Practical Application

Abstract

Data visualisation techniques are valuable tools for exploring, synthesising and communicating the results of research studies. Advanced data visualisation techniques, including dynamic and interactive visualisations, are just beginning to be used in health economics and outcome research (HEOR). In HEOR, there is the potential to use these techniques both to explore methodological challenges that are central to the design and interpretation of the findings of pharmacoeconomic and outcomes research studies, but also to communicate research findings to various stakeholders. In this manuscript, we discuss opportunities and methodological challenges for data visualisation specific to HEOR, describe external barriers that may impact the use of data visualisation methods, and discuss future applications of this technology in HEOR. While there are a number of obvious applications within the data-heavy field of HEOR, caution is required to ensure that visualisations, particularly advanced ones, accurately and fairly reflect the underlying data. However, researchers will benefit from adopting these increasingly sophisticated techniques to help ensure that decisionmakers and other stakeholders can understand, digest and communicate the data—which is critical for achieving the ultimate goal of improving patient outcomes.

Notes

Author Contributions

AJL and SMS were primarily responsible for drafting the manuscript, and all authors critically reviewed and edited the content. Participation in development of the visualisations was as follows: Pharmacist model: KMJ. Hodgkin lymphoma visualisation: KMJ, SMS. NMA visualisation: KMJ, SMS. Static Sankey plot: KMJ, SMS. Dynamic Sankey plot: AJL, SMS. Bivariate area chart: KMJ, AJL, SMS.

Compliance with Ethical Standards

Conflict of interest

SMS: none; KMJ: none; AJL: none.

Funding

None.

References

  1. 1.
    Healy K. Data visualization: A practical introduction. Woodstock: Princeton University Press; 2019.Google Scholar
  2. 2.
    Evergreen S. Effective data visualization: the right chart for the right data (Chapter 1). Los Angeles, CA: Sage; 2016.Google Scholar
  3. 3.
    Tufte E. The visual display of quantitative information (Chapter 1). 2nd ed. Cheshire, CT: Graphics Press; 2001. p. 13.Google Scholar
  4. 4.
    Munzer T. Visualization analysis & design. Boca Raton, FL: CRC; 2015. p. 116–44.Google Scholar
  5. 5.
    Evergreen S, Emery AK. Data visualization checklist. 2016 [cited 6-Feb-2019]; http://stephanieevergreen.com/wp-content/uploads/2016/10/DataVizChecklist_May2016.pdf.
  6. 6.
    Tufte E. The visual display of quantitative information (Chapter 5). 2nd ed. Cheshire, CT: Graphics Press; 2001. p. 136–7.Google Scholar
  7. 7.
    Munzer T. Visualization analysis & design. Oxford: CRC; 2015. pp. 1–20.Google Scholar
  8. 8.
    Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott). 2017;150(3):184–97.Google Scholar
  9. 9.
    Broadstreet HEOR. Canadian Pharmacists Association Hypertension app. 2017. https://cpha.broadstreetheor.com/. Accessed 11 Apr 2019.
  10. 10.
    Pietila M. How next generation data visualization tools enable real-time efficiencies in clinical trials. Pharmaceutical Outsourcing; 2018.Google Scholar
  11. 11.
    Szabo SM, Hirji I, Johnston KM, Juarez-Garcia A, Connors JM. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: a retrospective cohort study. PLoS One. 2017;12(10):e0180261.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Broadstreet HEOR. Costs of RRHL in the US. 2017. https://demo.eviviz.com/hodgkin/. Accessed 11 Apr 2019.
  13. 13.
    Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life R. Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. 2013;22(3):475–83.Google Scholar
  14. 14.
    Badger E, Miller CC, Pearce A, Quealy K. Extensive data shows punishing reach of racism for black boys. New York Times 2018 [cited 20-Nov-2018]. https://www.nytimes.com/interactive/2018/03/19/upshot/race-class-white-and-black-men.html. Accessed 11 Apr 2019.
  15. 15.
    Embretson S, Reise S. Item response theory for psychologists. Mahwah, NJ: Psychology Press; 2000.Google Scholar
  16. 16.
    Fazio L, Rosner A, Drummond M. How Do U.S. Payers use economic models submitted by life sciences organizations? Value Outcomes Spotl. 2016:18–21.Google Scholar
  17. 17.
    Canadian Agency for Drugs and Technology in Health (CADTH). Procedure and Submission Guidelines for the CADTH Common Drug Review 2018.Google Scholar
  18. 18.
    Yau N. How I made that animated difference plot in R. 2018 Available from: https://flowingdata.com/2018/11/09/how-i-made-that-animated-difference-charts-in-r/. Accessed 11 Apr 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Shelagh M. Szabo
    • 1
    Email author
  • Karissa M. Johnston
    • 1
  • Andrew J. Lloyd
    • 2
  1. 1.Broadstreet HEORVancouverCanada
  2. 2.AcasterLloyd ConsultingLondonUK

Personalised recommendations